

# Corporate Accountability for Tax Expenditures Act 93-552

## Annual Project Progress Reports for 2022

Xeris Pharmaceuticals, Inc.

Chicago

### I. Development Assistance Agreements Awarded in 2017

	Assistance Amount	Agreement Number
EDGE Tax Credit	782,984.91	17 ZCA1088

### II. Organization/Project Site Information

Chief Officer or authorized designee	Blaine Roeder
Title	Tax Director
Address	180 N LaSalle
	Suite 1600
	Chicago, IL 60601
	USA
Phone	312-517-1997
E-mail	broeder@xerispharma.com
Standard Industrial Classification Number (SIC#)	2834
North American Industry Classification System (NAICS)	325412

III. Did the recipient's use of the State Funding reduce employment at any other site in Illinois? No

# Corporate Accountability for Tax Expenditures Act 93-552

## Annual Project Progress Reports for 2022

Xeris Pharmaceuticals, Inc.

Chicago

### IV. Job Creation and Retention Data

**Program Type** EDGE Tax Credit

**Agreement Number** 17 ZCA1088

**Assistance Amount** 782,984.91

Report Header Definitions	
Wages	Average Annual Salary by Classifications
Full-Time	Permanent Full-Time
+/-	Gain or (Loss)

### Number of Employees At the Time of Application

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Headquarters	865000.00	3	3	0	0
Finance	185000.00	1	1	0	0
Marketing	175000.00	1	1	0	0
Operations	0.00	0	0	0	0
Clinical	0.00	0	0	0	0
IT	0.00	0	0	0	0
Legal	0.00	0	0	0	0
Quality Assurance	0.00	0	0	0	0
Regulatory	0.00	0	0	0	0
Medical Affairs	0.00	0	0	0	0
Sales	0.00	0	0	0	0
<b>Totals:</b>		<b>5</b>	<b>5</b>	<b>0</b>	<b>0</b>

# Corporate Accountability for Tax Expenditures Act 93-552

## Annual Project Progress Reports for 2022

Xeris Pharmaceuticals, Inc.

Chicago

### Number of Employees As of the Date of the Report (12/31/2022)

Job Classification	Avg Annual Salary	Positions	Full-Time	+/-	Part-Time	+/-	Temporary	+/-
Headquarters	275599.00	9	9	6	0	0	0	0
Finance	182158.00	12	12	11	0	0	0	0
Marketing	126660.00	10	10	9	0	0	0	0
Operations	176902.00	11	11	11	0	0	0	0
Clinical	148607.00	3	3	3	0	0	0	0
IT	142341.00	8	8	8	0	0	0	0
Legal	312254.00	3	3	3	0	0	0	0
Quality Assurance	161783.00	6	6	6	0	0	0	0
Regulatory	120682.00	2	2	2	0	0	0	0
Medical Affairs	300976.00	11	11	11	0	0	0	0
Sales	64440.00	51	51	51	0	0	0	0
<b>Totals:</b>		<b>126</b>	<b>126</b>	<b>121</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

### Number of Jobs Stated in the Agreement that would be Created at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Director of Business Development	175000.00	1	1	0	0
Finance	965000.00	8	8	0	0
Headquarters	235000.00	1	1	0	0
Marketing	250000.00	2	2	0	0
Operations	570000.00	3	3	0	0
Regulatory	235000.00	1	1	0	0
<b>Totals:</b>		<b>16</b>	<b>16</b>	<b>0</b>	<b>0</b>

### Number of Jobs Stated in the Agreement that would be Retained at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
NONE	0.00	0	0	0	0
<b>Totals:</b>		<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

# Corporate Accountability for Tax Expenditures Act 93-552

## Annual Project Progress Reports for 2022

Xeris Pharmaceuticals, Inc.

Chicago

### Number of Full-Time Permanent Employees Anticipated To Be Hired at this Site on 12/31/2022

Job Classification	Anticipated Starting Dates	Number of Positions to be Hired in this Category	Average Annual Wage per New Employee	Total New Payroll to be Created
NONE		0	\$0.00	\$0.00
<b>Totals:</b>		<b>0</b>		<b>\$0.00</b>

### Job Creation Data Explanatory Notes

If the change (gain/loss) in the number of full-time permanent employees as of the date of the report plus the number of full-time permanent employees anticipated to be hired after date of the report does not equal the number of full-time permanent employees stated in the Agreement that would be created at the site as a result of the assistance, then please explain why not:

Due to the expanding business, more employees were hired in the Chicago location than originally expected. Also, the Company expanded the Chicago Corporate Headquarters to facilitate the increase in headcount. A new 10-year lease was signed for additional square footage.

**Corporate Accountability for Tax Expenditures Act 93-552**

**Annual Project Progress Reports for 2022**

Xeris Pharmaceuticals, Inc.

Chicago

I, Steven M Pieper, as the chief officer or authorized designee of the recipient, verify that the information in the progress report contains no knowing misrepresentation of material facts upon which eligibility for development assistance is based. I further certify that, to the best of my knowledge, the recipient is in compliance with the development assistance agreement(s) between, or on behalf of, the recipient and the Illinois Department of Commerce and Economic Opportunity and/or the Illinois Department of Transportation and/or the office of the Illinois State Treasurer

**Signature on File**

\_\_\_\_\_  
Signature

**5/8/2023**

\_\_\_\_\_  
Date

**CFO**

\_\_\_\_\_  
Title